Month: October 2020

Moderna Inc (NASDAQ: MRNA)’s CEO said last week that it will not seek emergency use authorization for its coronavirus vaccine candidate mRNA-1273 before the Nov. 3 U.S. presidential election.Trial Enrollment Hits 94% Of Target: Moderna’s vaccine candidate is in a large-scale Phase 3 trial dubbed COVE with a target enrollment of 30,000 participants.About 28,043, or 93.5%, of the targeted participants have been enrolled into the study, Moderna said in a late Friday tweet.Of those people, 19,369 have been administered a second dose.> As of Friday, October 2, 2020, 28,043 participants have been enrolled in the Phase 3 COVE study …read more […]

September ended with a swoon.
The Dow Jones, the Nasdaq and the S&P 500 finished the month with declines. Their first monthly declines since March!
It’s been a fantastic, largely unfettered rally from the lows we saw earlier this year.
Investors are now starting to feel a little anxious. And there are plenty of headlines triggering clammy palms for traders.
So the question du jour is… Is this a “buy the dip” moment, or do we sit on the sidelines, happily nibbling on some pumpkin-spiced treat?
A Month of Scary Moves
October is home to one of my favorite holidays: Halloween.
But it’s not just ghouls and …read more […]

…read more […]

(Bloomberg) — Regeneron Pharmaceuticals Inc. climbed the most in more than three months on Monday after U.S. President Donald Trump received the biotech company’s antibody cocktail to treat Covid-19.President Trump’s treatment was the “ultimate validation” for Regeneron, according to SVB Leerink analyst Geoffrey Porges.Like Regeneron, Eli Lilly & Co. and AbCellera Biologics Inc. are developing an antibody therapy, not only as a treatment for the virus but also as a preventative. When used as a prophylactic, these products could be considered a passive vaccine as opposed to the active shots most people think of as a vaccine, Bloomberg Intelligence’s Sam …read more […]

Yahoo Finance’s Emily McCormick joins Kristin Myers to discuss JP Morgan’s new price target on Tesla. …read more […]

Note from Managing Editor Allison Brickell: We get a lot of questions about gold here at Liberty Through Wealth. So today we thought we’d bring in one of the “gold guys” – Rich Checkan, president and chief operating officer of Asset Strategies International. Rich always has his finger on the pulse of the precious metals market. He’s also one of The Oxford Club’s Pillar One Advisors. Oxford Club Members can find more information about Rich and his company here.

I was manning my exhibit booth at The Oxford Club’s Investment U Conference. It was the spring of 2009. After Alexander Green’s …read more […]

(Bloomberg) — Companies have been selling risky loans to fund payouts at the fastest pace in years. Harbor Freight Tools USA Inc., a discount tools retailer run by billionaire Eric Smidt, is the latest borrower looking to line its pockets.The company, which sells $7.99 wrenches and $8.99 plier sets, is seeking to borrow $3 billion in what will be its fifth such deal in the past decade, according to data compiled by Bloomberg.It plans to use some of the proceeds to refinance existing debt and the rest for a dividend, according to a person familiar with the matter. Credit Suisse …read more […]

Just because a business does not make any money, does not mean that the stock will go down. For example, although… …read more […]

Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of… …read more […]

…read more […]

Every investor in Tilray, Inc. (NASDAQ:TLRY) should be aware of the most powerful shareholder groups. Institutions… …read more […]

Today we’re going to take a look at the well-established Microsoft Corporation (NASDAQ:MSFT). The company’s stock… …read more […]

Marvell Technology Group (NASDAQ:MRVL) has had a great run on the share market with its stock up by a significant 12… …read more […]

Dr. Darria Long, ER Physician and Clinical Assistant Professor at University of Tennessee School of Medicine, joins Yahoo Finance’s Zack Guzman to discuss Trump’s COVID-19 prognosis …read more […]